August 22, 2017 5:39pm

 

A response to speculation and oversold conditions

While sentiment is overlooked and volume is still very low

 

As I had stated this a.m., “buy the oversold at a bottom and bid’em up to exit as many become overbought.”

 

Pre-open indications:  3 hits and 1 miss

Out and about: Biostage (BSTG) makes yet another low of -5.27% or -0.0148 to $0.26 after being down -10.44% to $0.25, a far cry from Q1/17’s start at $0.87, Q1/16’s $2.60, Q1/15’s $4.43 … a “walking dead” company who can’t even get an IND filed as their proof of concept was found “unable to be filed” having burned through $30 M and whose current +$3 M funding is all about salary continuation with a new development “tunnel ”! And I was initially their biggest supporter …

 

It’s called premium content for a reason … I define insight  from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!

Others don’t even come close!

 

I answer one question, in which company should investors commit and keep their money.

 


 

Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s investor’s newsletter, “…yesterday you drunk the humpty-dumpty. A hangover remedy is needed, probably another shot … To balance out the aftermath even when indexes gain as share pricing falls.”

  • Volume is still very low as share pricing jumps – a soon to be crisis?

Speculation is running rampart as low volume upticks can quickly become downdrafts!

  • Remember, “Our” universe’s volatility isn’t about fear, but about doubts about sustainability, viability of share pricing and conviction.

I continue to believe that, there is a BIG disconnect between investors who are getting more disgusted in the dips and drips of the sector and managements who are NOT waking up to the reality of stake holder loyalty and its rapid decline!

 

Are CEOs willing to leave their share pricing dependent on an algorithm and ETF? You betcha' ...!! 

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour was positive with an A/DL of 23/11 and 9 flats;

·         The mid-day was positive with an A/DL of 32/26 and 1 flat;

·         The close was positive  with an A/DL of 28/11 and 4 flat;

 

 

Pre-open indications: 3 hits and 1 miss

  • Applied Genetic Technologies (AGTC) closed up +$0.05 – hit;
  • Cellectis SA (CLLS) closed up +$1.06 – hit;
  • Kite Pharma (KITE) closed up +$2.65 – miss;
  • Pluristem (PSTI) closed down -$0.015 – hit;

 

 

Regenerative Medicine Earnings Scorecard - Q2/2017 - to date – so far

http://www.regmedinvestors.com/articles/9841

 

 

Daily analytics:

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Tuesday traded at 11.40, down -13.57% 

  • Monday traded at 13.08, down -7.57% … Friday traded 14.22, down -8.55% after Thursday traded 15.55, up +32.45% while Wednesday traded at 11.74, down -2.49%, after last Tuesday traded at 12.04, down -2.35%,

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Tuesday was up +1.08%

·         Monday -0.04%

·         Friday -0.03%

·         Thursday -1.80%

·         Wednesday +0.04%

·         Last Tuesday -0.81%

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Tuesday was up +1.92%

·         Monday +0.20%

·         Friday -0.25%

·         Thursday -1.70%

·         Wednesday +0.25%

·         Last Tuesday +0.09%

 

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

·         Tuesday’s decliners ranged from -0.57% <HSGX -$0.01> to -5.27% <BSTG -$0.0148> in 11 equities;

·         Monday’s decliners ranged from -0.30% <IMUC -$0.001> to -6.75% <NWBO -$0.0135> in 20 equities;

·         Friday’s decliners ranged from -0.13% <OPXA -$0.001> to -13.01% <BSTG -$0.04> in 23 equities;

·         Thursday’s decliners ranged from -0.48% <BCLI> to -9.71% <RGNX> in 30 equities;

·         Wednesday’s decliners ranged from -0.31% <BSTG> to -5.36% <SGMO> in 21 equities;

·         Last Tuesday’s decliners ranged from -0.38% <FCSC> to -15.29% <BSTG> in 24 equities;

 

Versus

… Look at the percentage’s (%) and spreads …

·         Tuesday’s gainers ranged from +0.33% <OSIR +$0.02> to +20.25% <OPXA +$0.16> in 28 equities;

·         Monday’s gainers ranged from +0.22% <BLUE +$0.20> to +5.74% <OPXA +$0.04> in 14 equities;

·         Friday’s gainers ranged from +0.48% <BCLI +$0.02> to +9.89% <NWBO -$0.02> in 17 equities;

·         Thursday’s gainers ranged from +0.23% <QURE> to +14.33% <IMUC> in 9 equities;

·         Wednesday’s gainers ranged from +0.05% <BLUE> to +7.44% <IMUC> in 21 equities;

·         Last Tuesday’s gainers ranged from +0.43% <XON> to +6.08% <MDXG> in 15 equities;

 

 

Some of MY working trend lines or indications:

… The greatest volume to the downside:  BSTG, NWBO, ATHX, CAPR and BCLI

… Upside volume was weighted to:  IMUC, MDXG, KITE, SGMO and JUNO

… Biggest $ downside:  MESO, BCLI, ISCO, CLBS and ATHX

… Largest $ upside:  BLUE, ONCE, KITE, CLLS, JUNO and RGNX

… Flat:  ADVM, CUR, RENE.L and QURE

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.